High prevalence of human T-cell leukemia virus type-1b genotype among blood donors in Gabon, Central Africa.
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
23
08
2019
revised:
26
02
2020
accepted:
22
03
2020
pubmed:
18
5
2020
medline:
23
6
2021
entrez:
17
5
2020
Statut:
ppublish
Résumé
The African continent is considered to be the largest endemic area of HTLV-1 infection, with at least several million infected individuals. Systematic screening of blood donors can prevent the transmission of HTLV-1 in blood. Gabon is one of the countries with the highest prevalence of HTLV-1 worldwide, and yet the routine testing of blood donors has still not been introduced. All blood donations collected between April and July 2017 at the Centre National de Transfusion Sanguine of Gabon were studied. Plasma samples were screened by ELISA for the presence of HTLV-1/2 antibodies. Western blot (WB) and polymerase chain reaction (PCR) tests were used for confirmation. In total, 3123 blood donors were tested, including 1740 repeat and 1378 first-time blood donors (FTBDs). Of them, 132 samples tested positive for HTLV-1/2 by ELISA (4.2%). WB and PCR confirmed HTLV-1 infection for 23 individuals. The overall prevalence of HTLV-1 was 0.74% [95% CI 0.47%-1.10%], 1% in FTBD, and 0.5% in repeat donors. Age and sex-adjusted prevalence was five-fold lower in FTBD than in the general adult population of rural areas of Gabon. All detected HTLV-1 strains belonged to the central African HTLV-1b genotype but were highly diverse. We report an overall prevalence of HTLV-1 of 0.74%, one of the highest values reported for blood donors in Africa. Given the high risk of HTLV-1 transmission in blood, it is necessary to conduct cost-effectiveness studies to determine the need and feasibility of implementing screening of HTLV-1 in blood donors in Gabon.
Sections du résumé
BACKGROUND
The African continent is considered to be the largest endemic area of HTLV-1 infection, with at least several million infected individuals. Systematic screening of blood donors can prevent the transmission of HTLV-1 in blood. Gabon is one of the countries with the highest prevalence of HTLV-1 worldwide, and yet the routine testing of blood donors has still not been introduced.
METHODS
All blood donations collected between April and July 2017 at the Centre National de Transfusion Sanguine of Gabon were studied. Plasma samples were screened by ELISA for the presence of HTLV-1/2 antibodies. Western blot (WB) and polymerase chain reaction (PCR) tests were used for confirmation.
RESULTS
In total, 3123 blood donors were tested, including 1740 repeat and 1378 first-time blood donors (FTBDs). Of them, 132 samples tested positive for HTLV-1/2 by ELISA (4.2%). WB and PCR confirmed HTLV-1 infection for 23 individuals. The overall prevalence of HTLV-1 was 0.74% [95% CI 0.47%-1.10%], 1% in FTBD, and 0.5% in repeat donors. Age and sex-adjusted prevalence was five-fold lower in FTBD than in the general adult population of rural areas of Gabon. All detected HTLV-1 strains belonged to the central African HTLV-1b genotype but were highly diverse.
CONCLUSION
We report an overall prevalence of HTLV-1 of 0.74%, one of the highest values reported for blood donors in Africa. Given the high risk of HTLV-1 transmission in blood, it is necessary to conduct cost-effectiveness studies to determine the need and feasibility of implementing screening of HTLV-1 in blood donors in Gabon.
Identifiants
pubmed: 32415686
doi: 10.1111/trf.15838
pmc: PMC7496943
doi:
Substances chimiques
Antigens, Viral
0
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1483-1491Subventions
Organisme : Agence Nationale de la Recherche
ID : LabEx ANR10-LBX-62 IBEID
Organisme : Centre National de la Recherche Scientifique
ID : UMR 3569
Organisme : European Commission
ID : FOOD/2016/379-660
Informations de copyright
© 2020 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB.
Références
N Engl J Med. 1990 Feb 8;322(6):383-8
pubmed: 2300089
Transfusion. 2009 Jun;49(6):1146-50
pubmed: 19222818
PLoS Negl Trop Dis. 2018 Oct 12;12(10):e0006832
pubmed: 30312301
Viruses. 2016 Feb 03;8(2):
pubmed: 26848683
AIDS Res Hum Retroviruses. 2012 Oct;28(10):1265-72
pubmed: 22324906
Transfusion. 1994 Jun;34(6):478-83
pubmed: 8023388
Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(4):152-66
pubmed: 21558754
J Clin Microbiol. 2008 Nov;46(11):3607-14
pubmed: 18845819
Vox Sang. 2019 Jul;114(5):413-425
pubmed: 30972789
Transfus Med Rev. 2012 Apr;26(2):119-28
pubmed: 21871776
J Hum Virol. 1998 May-Jun;1(4):302-5
pubmed: 10195256
J Clin Microbiol. 2006 Apr;44(4):1550-4
pubmed: 16597891
Vox Sang. 2019 Jul;114(5):467-477
pubmed: 31131453
Int J Cancer. 1988 Nov 15;42(5):687-9
pubmed: 3182104
PLoS Negl Trop Dis. 2018 Oct 25;12(10):e0006833
pubmed: 30359373
Vox Sang. 2019 Jul;114(5):451-458
pubmed: 30950074
Front Microbiol. 2012 Nov 15;3:388
pubmed: 23162541
Front Microbiol. 2012 Sep 10;3:322
pubmed: 22973265
Transfus Clin Biol. 2014 Nov;21(4-5):167-72
pubmed: 25267203
BMC Pregnancy Childbirth. 2017 Jun 12;17(1):185
pubmed: 28606185
Transfusion. 2016 Jan;56(1):249-60
pubmed: 26388300
J Acquir Immune Defic Syndr (1988). 1993 Mar;6(3):324-5
pubmed: 8450411
Transfusion. 2002 Jun;42(6):780-91
pubmed: 12147033
Rev Med Virol. 2018 Mar;28(2):
pubmed: 29380451
Vox Sang. 2017 Nov;112(8):723-732
pubmed: 28960337
Bull Soc Pathol Exot. 1993;86(1):12-5
pubmed: 8099298
Transfus Med. 2013 Oct;23(5):358-66
pubmed: 23859527
Int J Epidemiol. 2000 Dec;29(6):1076-84
pubmed: 11101551
Transfusion. 2003 Feb;43(2):226-34
pubmed: 12559018
Int J Cancer. 1992 Jul 30;51(6):886-91
pubmed: 1639536
Transfus Med. 1995 Jun;5(2):135-7
pubmed: 7655577
Transfus Clin Biol. 2016 Feb;23(1):13-9
pubmed: 26778839
J Virol. 1997 Feb;71(2):1317-33
pubmed: 8995656
Lancet Child Adolesc Health. 2019 Apr;3(4):264-273
pubmed: 30878119
Transfusion. 2013 Oct;53(10):2168-75
pubmed: 23384161
J Acquir Immune Defic Syndr (1988). 1993 Apr;6(4):424-8
pubmed: 8455148
J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):187-92
pubmed: 8680891
Nat Rev Dis Primers. 2015 Jun 18;1:15012
pubmed: 27188208
Int J Epidemiol. 1994 Aug;23(4):812-7
pubmed: 8002196
Int J Cancer. 1991 Sep 30;49(3):373-6
pubmed: 1917135
J Acquir Immune Defic Syndr. 1999 Nov 1;22(3):314-5
pubmed: 10770357
Transfusion. 1993 Jan;33(1):14-8
pubmed: 8424263